Clinical trials: Cancer Vaccine
Human Papilloma Virus (HPV) Vaccine
Knowledge, Attitude &Practice on Human Papilloma Virus Vaccination Among Healthcare Providers and General Population
Cervical cancer is caused by persistent infection with certain strains of the human papillomavirus (HPV), which is a very common virus transmitted through sexual activity.
- Trial name
- NCT06743880
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Assiut University
Human Papillomavirus Infection
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
This is a randomized, open label trial of HPV (human papilloma virus) vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose.
- Trial name
- NCT00572832
- Testing
- Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP)
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of…
- Conditions
- Human Papillomavirus (HPV) Vaccine, Human Papillomavirus (HPV) Vaccines, Human Papillomavirus (HPV) Infections, Adolescent Health Services
- Trial name
- SHARP (NCT07200414)
- Testing
- Integrated Adolescent Health Package, Routine Government Health Services
- Where
- Nigeria
- Volunteers
- 12,654 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HPV Infections
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9…
- Trial name
- NCT03900572
- Testing
- HPV Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Meningococcal Infection
Immunogenicity of the Booster Dose of Two MenC Vaccines
The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to assess the interchangeability of the two…
- Trial name
- CSISP-MENC1 (NCT00392808)
- Testing
- conjugated polysaccharide menC vaccine
- Where
- 2 sites in Spain
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Centro Superior de Investigación en Salud Publica
HPV Infection, Health Behavior
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
The MDL-SHPVP will be developed and a clustered randomised controlled trial will be conducted to evaluate the effects of the MDL-SHPVP and to examine whether the effect of the MDL-SHPVP on the rate of HPV vaccine uptake 1 year…
- Conditions
- HPV Infection, Health Behavior, Health Attitude
- Trial name
- NCT04438291
- Testing
- MDL-SHPVP, 30-minute educational video
- Where
- Hong Kong
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Human Papilloma Virus Infection
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
This trail is to evaluate the safety profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy Chinese women ages 20-45 and determine the optimal ratio of…
- Trial name
- NCT05694728
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)
- Where
- China
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Cervical Intraepithelial Neoplasia, Cervical Cancer
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
This is a bridging trial of the recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.The primary objective of this study is to evaluate the immunogenicity (type specific IgG antibody) and safety…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT02562508
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Human Papillomavirus, Uterine Cervical Neoplasms
An HPV Vaccine Provider Intervention in Safety Net Clinics
The purpose of this study is to develop, deliver and evaluate a provider intervention for mothers and their children to encourage receipt of the human papillomavirus (HPV) vaccine in the children and appropriate cervical cancer…
- Trial name
- NCT02808832
- Testing
- Educational materials
- Where
- United States
- Volunteers
- 806 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
Cervical Cancer, Anogenital Warts
Evaluation of Long Term Immunity Following HPV Vaccination
In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil®…
- Trial name
- NCT02276521
- Testing
- Cervarix®
- Where
- Fiji
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Human Papillomavirus Infection, HPV Vaccination
THE EFFECTS OF HPV VACCİNATİON AND MESSAGE FRAMİNG
Background: University students are at high risk for HPV infection, while HPV vaccination rates remain low. Message framing strategies may influence vaccination-related perceptions and intentions.
- Conditions
- Human Papillomavirus Infection, HPV Vaccination, Vaccine Hesitancy
- Trial name
- NCT07614009
- Testing
- Gain-Framed HPV Vaccination Message, Loss-Framed HPV Vaccination Message
- Where
- Turkey (Türkiye)
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- Ankara Medipol University
The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines
Human pancreatic cancer has a very poor prognosis with an overall survival rate of less than 5%. Current treatment regimens are ineffective and even if the patient responds to initial treatments, relapse is common due to the…
- Trial name
- CanVac (NCT04379960)
- Testing
- Peptides
- Where
- United Kingdom
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Cervical Cancer, Anal Cancer
A Chatbot Intervention for Reducing HPV Vaccine Hesitancy
The goal of this project is to test the efficacy of a chatbot intervention for reducing HPV vaccine hesitancy among African American parents.
- Conditions
- Cervical Cancer, Anal Cancer, Penile Cancer
- Trial name
- NCT05959564
- Testing
- Personalized Chatbot Intervention, Non-Personalized Chatbot Intervention, No Chatbot Control
- Where
- United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Cervical Neoplasia, HPV Infections
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Background: National Cancer Institute Protocol 04-C-N191, also known as the Costa Rica Vaccine Trial, was a double-blind controlled study of the effectiveness of an experimental human papillomavirus (HPV) vaccine in preventing…
- Trial name
- NCT01086709
- Where
- Costa Rica
- Volunteers
- 5,444 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)